Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease
Vaccination against coronavirus disease 2019 (COVID-19) has become an important public health solution. Developing a safe and effective vaccine against COVID-19 is a viable long-term solution to control the pandemic. As one of the two inactivated severe acute respiratory syndrome virus 2 (SARS-CoV-2...
Main Authors: | Chao Wang, Lin-Yi Chen, Qing-Bin Lu, Fuqiang Cui |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/10/6/920 |
Similar Items
-
Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine
by: Chandima Jeewandara, et al.
Published: (2022-06-01) -
Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco
by: Yaowen Zhang, et al.
Published: (2022-08-01) -
The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 nucleocapsid, besides spike protein in healthy adults
by: Qinjin Wang, et al.
Published: (2022-11-01) -
RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine
by: Tamás Ferenci, et al.
Published: (2022-01-01) -
Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand
by: Saraiorn Thonginnetra, et al.
Published: (2022-10-01)